Cholangiocarcinoma Foundation

The mission of the Cholangiocarcinoma Foundation (CCF) is to find a cure and improve the quality of life for those affected by cholangiocarcinoma, a rare fatal cancer that originates from the cells in the lining of the bile ducts. Founded in 2006 by a family of a loved one who was lost to cholangiocarcinoma, CCF has grown to become a renown, global non-profit organization funding research and providing support and education to the cholangiocarcinoma community at-large.

Latest from Cholangiocarcinoma Foundation

Cholangiocarcinoma Drug Pulled From Market, Other Options Still Viable

June 05, 2024

Article

While the FDA approval of Truseltiq for FGFR2-positive cholangiocarcinoma was withdrawn, there are still other viable treatment options, an expert said.

Keytruda-Chemo Combo Can ‘Reduce Risk of Death’ in Biliary Tract Cancer

November 15, 2023

Article

Keytruda plus chemotherapy for patients with locally advanced biliary tract cancer helped increase survival for up to two more years, an expert told CURE®.

Balancing Scientific Rigor With Empathy in Cancer Care

June 03, 2022

Article

Although she has always been driven to excel, Karen Driskill's, M.S., RN, purpose became more focused after her mother-in-law passed away from intrahepatic cholangiocarcinoma in 2010.

‘Majority of Patients’ With Cholangiocarcinoma Still Receive Upfront Standard of Care Despite Recent FDA Drug Approvals

March 08, 2022

Video

Despite several FDA drug approvals over the past few years in the cholangiocarcinoma space, many patients are ineligible for these treatments as a first option, signaling a significant unmet need.

9th Annual Cholangiocarcinoma Foundation Conference Features Expert Speakers, 40 Poster Presentations From Around The World

February 16, 2022

Article

Mark R. Clements awards bestowed to three individuals at annual conference, Feb. 23-25th.

Cholangiocarcinoma Foundation Congratulates Astrazeneca TOPAZ-1, the First Phase III Trial to Show Adding Immunotherapy to Standard Chemotherapy Can Increase Overall Survival in Advanced Biliary Tract Cancer

January 25, 2022

Article

On behalf of patients and families impacted by cholangiocarcinoma (bile duct cancer), the Cholangiocarcinoma Foundation congratulates AstraZeneca and its positive results from the TOPAZ-1 Phase III trial.